Oncology
Latest news
915 articles · 20 / page
Twice-Weekly All-Oral Ixazomib, Pomalidomide, and Dexamethasone Shows Durable Activity in Relapsed/Refractory Multiple Myeloma
A phase I/II study suggests twice-weekly ixazomib plus pomalidomide-dexamethasone is a feasible all-oral option in relapsed/refractory multiple myeloma, with a 65.8% response rate at the RP2D and manageable hematologic toxicity.
Anti-CD117 Conditioning With Briquilimab Shows Feasibility and Stem-Cell Depletion in Older Adults Undergoing Allogeneic Transplant for High-Risk AML and MDS
A phase 1 trial suggests briquilimab can be safely added to nonmyeloablative conditioning before allogeneic transplant in older adults with high-risk AML or MDS, with biologic evidence of hematopoietic stem/progenitor cell depletion and enc
Pancreatic Cancer Risk During IPMN Surveillance Is About 10-Fold Higher Than in the General Population
A SEER-matched analysis found that patients undergoing IPMN surveillance have a markedly elevated malignancy risk, with substantial heterogeneity by duct dilation, obesity, age, and cyst features.
Pancreatic Cancer Risk During IPMN Surveillance: A SEER-Based Comparison
A SEER-based study found IPMN surveillance patients have about 10 times higher pancreatic cancer risk than the general population, with highest risk in those with main duct dilation or obesity.
More Than Half of Patients With Atypical Endometrial Hyperplasia Had Occult Cancer at Hysterectomy in a Minority-Enriched Urban Cohort
A single-center retrospective study found unexpectedly high rates of concurrent endometrial carcinoma and Mayo-criteria risk features among patients with atypical endometrial hyperplasia in a predominantly racial and ethnic minority populat
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer
A national study of veterans with cancer found elevated suicide-related risk that persisted for years, especially among younger, unmarried, frail, or mentally ill patients and those with certain cancers such as central nervous system and th
Targeting Ibrutinib Resistance Pathways with miR-28 in ABC-DLBCL
miR-28 suppresses the emergence of ibrutinib resistance in ABC-DLBCL by disrupting clonal selection and dampening mitochondrial and mTOR signaling, with promising preclinical nanoparticle delivery results.
When Severe Mental Illness Meets Lung Cancer: Why Equal Treatment Still Isn’t Guaranteed
A large Japanese study found that people with schizophrenia spectrum disorders were less likely to receive several standard treatments for non-small cell lung cancer, underscoring a persistent and preventable gap in cancer care.
Patients With Schizophrenia Spectrum Disorder Are Less Likely to Receive Stage-Appropriate Treatment for Non-Small Cell Lung Cancer in Japan
A nationwide Japanese cohort study found that patients with schizophrenia spectrum disorder and NSCLC presented with more advanced disease and were less likely to receive surgery, adjuvant chemotherapy, or systemic therapy.
Embedding Tobacco Treatment Into Cancer Care Achieved Universal Screening but Exposed Persistent Gaps in Cessation Assistance
A cancer program quality improvement initiative reached a 100% smoking-status ask rate through an electronic hard stop, but assistance for identified smokers remained inconsistent, underscoring the implementation gap between screening and e
Beyond Extrapolation: Immunotherapy Outcomes in Recurrent Vulvovaginal Carcinoma
This retrospective study found that immune checkpoint inhibitors produced modest overall benefit in recurrent vulvar and vaginal carcinoma, but a small subset of patients had durable responses lasting months.
Targeting Oncomucin-Driven Immunosuppression Improves KRAS G12D Inhibition in Pancreatic Cancer
Oncomucins such as MUC4 and MUC16 help pancreatic cancer evade immunity through EGFR/UNC5B signaling. Targeting these mucins may enhance KRAS G12D inhibitor efficacy and reduce tumor burden.
Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX Models
MD-265, a PROTAC MDM2 degrader, showed strong anti-leukemia activity in primary AML cells and mouse PDX models, outperformed a conventional MDM2 inhibitor, and spared normal stem cells relatively well.
Volumetric Thresholds After Glossectomy May Predict Feeding Tube Dependence and Poor Speech
A retrospective cohort study suggests that preoperative tumor burden, extent of tongue resection, and degree of volume restoration are strongly associated with swallowing and speech outcomes after glossectomy.
Most Patients With Uncertain Response After Neoadjuvant Chemoradiotherapy for Esophageal Cancer Still Harbor Residual Disease
In the SANO cohort, 85% of patients with uncertain post-chemoradiotherapy response had residual tumor at esophagectomy, supporting surgery for most, while highlighting a notable complete response subgroup among squamous cell carcinoma with
Molecular and Spatial Differences in the Tumor Microenvironment of High-Grade Serous Ovarian Cancer With Short vs Long-Term Survival
This study found that advanced high-grade serous ovarian cancers from short-term survivors had more fibroblasts and stromal invasion signals, while tumors from long-term survivors showed stronger immune pathways, suggesting the tumor microe
PTEN Loss Drives MHC-I Evasion and Checkpoint Resistance in Microsatellite Stable Colorectal Cancer via NRF2-Dependent Autophagy
A Gut study links PTEN deficiency in MSS colorectal cancer to NRF2-driven autophagic loss of MHC-I, impaired CD8+ T-cell surveillance, and resistance to anti-PD-1 therapy, while identifying NRF2 inhibition as a potential sensitizing strateg
Intraperitoneal and Intravenous Paclitaxel Plus S-1 Improves Survival in Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
Anti-EBV BNLF2b Antibody Shows High Accuracy for Outpatient Diagnosis of Suspected Nasopharyngeal Carcinoma
In a prospective multicenter cohort, P85-Ab achieved 93.0% sensitivity and 97.3% specificity for suspected nasopharyngeal carcinoma, outperforming conventional EBV serologies in outpatient practice.
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial and Comparative Synthesis
This review synthesizes the BRIGHT-2 trial findings and meta-analytical data, confirming that bireociclib plus fulvestrant significantly improves progression-free survival in HR+/HER2- advanced breast cancer.
Browse by specialty
Open language-specific specialty feeds and department pages.